Immunity to Calicivirus Infection

The evolution of our understanding of immunity to calicivirus infection, using Norwalk virus as the prototype, is discussed in three stages: (1) “ancient times” (1972–1978), when human volunteer studies prevailed, (2) the “middle ages” (1978–1990), which were characterized by the development and imp...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2000-05, Vol.181 (Supplement-2), p.S331-S335
Main Authors: Matsui, Suzanne M., Greenberg, Harry B.
Format: Article
Language:English
Subjects:
Adults
Animals
Antibodies
Biological and medical sciences
Caliciviridae Infections - immunology
Children
Diseases
Gastroenteritis
Human calicivirus
Human viral diseases
Humans
Immunity
Infections
Infectious diseases
Medical sciences
Norwalk virus
Norwalk virus - immunology
Viral diseases
Viral diseases of the digestive system
Virion - immunology
Virology, Immunity, and Pathogenesis
Viruses
Volunteerism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The evolution of our understanding of immunity to calicivirus infection, using Norwalk virus as the prototype, is discussed in three stages: (1) “ancient times” (1972–1978), when human volunteer studies prevailed, (2) the “middle ages” (1978–1990), which were characterized by the development and implementation of solid-phase immunoassays based on native viral antigens, and (3) “modern times” (1990 to present), which began with the cloning of the genome of the noncultivatable 8FIIa strain of Norwalk virus and resulted in a readily available source of recombinant virus-like particles that have revolutionized the study of caliciviruses. Throughout these stages, it has been shown repeatedly that short-term immunity develops to homologous virus. However, the search for determinants of long-term immunity continues. These studies will likely be facilitated by the newest reagents—the noninfectious recombinant virus-like particles—used in the setting of human volunteer studies and large epidemiologic studies.
ISSN:0022-1899
1537-6613
DOI:10.1086/315587